热门资讯> 正文
DiaMedica Therapeutics GAAP每股收益为-0.18美元在线
2025-05-14 15:25
- DiaMedica Therapeutics press release (NASDAQ:DMAC): Q1 GAAP EPS of -$0.18 in-line.
- Cash Position and Runway – Cash, cash equivalents and short-term investments were $37.3 million as of March 31, 2025, compared to $44.1 million as of December 31, 2024. Based on its current plans, the Company anticipates its current cash, cash equivalents and short-term investments will enable the Company to fund its planned clinical studies and support corporate operations into the third quarter of 2026.
- Net cash used in operating activities for the quarter ended March 31, 2025 was $7.1 million compared to $6.7 million for the same period in 2024.
More on DiaMedica Therapeutics
- DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve
- DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript
- DiaMedica Therapeutics GAAP EPS of -$0.60 misses by $0.01
- Seeking Alpha’s Quant Rating on DiaMedica Therapeutics
- Historical earnings data for DiaMedica Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
